



CORONAVIRUS Peptides



About SARS CoV-2



SARS-CoV-2 Genes

SARS-CoV-2 has been shown to have four structural proteins, spike glycoprotein, envelope, membrane, and nucleocapsid proteins, as well as several non-structural proteins.

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) belongs to the family of coronaviruses. The novel coronavirus is responsible for the current COVID-19 pandemic.

COVID-19 Cytokine Storm Pathway

The recent pandemic has led to a large number of requests for SARS-CoV-2 related peptide products. In response, Abcepta has developed a complete coverage of 966 antigen-specific SARS-CoV-2 peptides. Applications for SARS-CoV-2 peptides include:

- T cell stimulation
- Immune monitoring
- Epitope discovery
- Target discovery
- T cell assays

Cytokine Storm Syndromes




Cell type	IFN γ	IL1b	IL6	IL17	IL18	IL23	TNF α
Dendritic cell							•
Endothelium		•			•		
Fibroblast			•		•		
Macrophage		•	•		•		•
T-cell	•		•	•	•	•	•

Massive cytokine release, known as **Cytokine storm** due to extensive **T-cell** activation is a driver of pathology during viral infections such as influenza. Cytokine release syndromes are a systemic inflammatory response with broad clinical conditions, including response against SARS CoV-2 and other coronaviruses.

IFN γ	IL1b	IL6	IL17	IL18	IL23	TNF α	Clinical condition
	•						Acute kidney injury
	•	•					Acute phase protein
		•					Anemia
			•			•	Atopic dermatitis
•					•	•	Crohn's disease, Ulcerative colitis
•						•	Debilitating
•						•	Decreased serum protein
•		•				•	Disseminated intravascular coagulation
•						•	Fever
•						•	Hyperlipidemia
•						•	Imaired hematopoiesis
•	•					•	Liver damage
						•	Psoriasis
						•	Spondyloarthritis
						•	Rheumatoid arthritis (RA)

References
Cytokine Growth Factor Rev (2020) 53 38-42
Nat Rev Immunol (2020) 20(9):271-27
J Immunother Cancer (2018) 6(1):156



Count on Abcepta's Antibodies & Services